Last reviewed · How we verify
epoetin beta [NeoRecormon]
Epoetin beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Epoetin beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients with HIV infection receiving antiretroviral therapy.
At a glance
| Generic name | epoetin beta [NeoRecormon] |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Epoetin beta is a glycoprotein produced by recombinant DNA technology that mimics endogenous erythropoietin (EPO). It binds to EPO receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity of the blood.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
- Anemia in patients with HIV infection receiving antiretroviral therapy
- Perioperative anemia in patients undergoing elective surgery
Common side effects
- Hypertension
- Headache
- Arthralgia
- Injection site reactions
- Thrombotic events (venous thromboembolism)
- Pure red cell aplasia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- epoetin beta [NeoRecormon] CI brief — competitive landscape report
- epoetin beta [NeoRecormon] updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI